Literature DB >> 11103791

Functional analysis of human ornithine decarboxylase alleles.

Y Guo1, R B Harris, D Rosson, D Boorman, T G O'Brien.   

Abstract

It has been known for > 10 years that there are two alleles of the human ornithine decarboxylase (ODC) gene, defined by a polymorphic PstI RFLP in intron 1. We have sequenced a large portion of each of the two alleles, including some of the 5' promoter region, exon 1, intron 1, and exon 2, and determined that a single nucleotide polymorphism at base +317 (relative to transcription start site) is responsible for the presence or absence of the PstI restriction site. We have developed two genotyping assays, a PCR-RFLP assay and a high-throughput TaqMan-based method, and determined the ODC genotype distribution in >900 North American DNA samples. On the basis of its location between two closely spaced Myc/Max binding sites (E-boxes), we speculated that the single nucleotide polymorphism at base +317 could have functional significance. Results of transfection assays with allele-specific reporter constructs support this hypothesis. The promoter/regulatory region derived from the minor ODC allele (A allele) was more effective in driving luciferase expression in these assays than the identical region from the major allele (G allele). Our results suggest that individuals homozygous for the A allele may be capable of greater ODC expression after environmental exposures, especially those that up-regulate c-MYC expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11103791

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention.

Authors:  Elizabeth L Barry; Leila A Mott; Robert S Sandler; Dennis J Ahnen; John A Baron
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-19

Review 2.  A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia.

Authors:  J T Cross; E M Poole; C M Ulrich
Journal:  Pharmacogenomics J       Date:  2008-01-15       Impact factor: 3.550

3.  Association between the ornithine decarboxylase G316A polymorphism and breast cancer survival.

Authors:  Linping Xu; Jianping Long; Peng Wang; Kangdong Liu; Ling Mai; Yongjun Guo
Journal:  Oncol Lett       Date:  2015-05-12       Impact factor: 2.967

4.  Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.

Authors:  Jason A Zell; Christine E McLaren; Wen-Pin Chen; Patricia A Thompson; Eugene W Gerner; Frank L Meyskens
Journal:  J Natl Cancer Inst       Date:  2010-08-26       Impact factor: 13.506

5.  Loss of the eukaryotic initiation factor 3f in melanoma.

Authors:  Adriana Doldan; Anupama Chandramouli; Reneé Shanas; Achyut Bhattacharyya; Stanley P L Leong; Mark A Nelson; Jiaqi Shi
Journal:  Mol Carcinog       Date:  2008-10       Impact factor: 4.784

Review 6.  Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.

Authors:  Nicholas F Evageliou; Michael D Hogarty
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

7.  Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival.

Authors:  Jason A Zell; Argyrios Ziogas; Natalia Ignatenko; Jane Honda; Ning Qu; Alexander S Bobbs; Susan L Neuhausen; Eugene W Gerner; Hoda Anton-Culver
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

8.  Loss of the eukaryotic initiation factor 3f in pancreatic cancer.

Authors:  Adriana Doldan; Anupama Chandramouli; Reneé Shanas; Achyut Bhattacharyya; John T Cunningham; Mark A Nelson; Jiaqi Shi
Journal:  Mol Carcinog       Date:  2008-03       Impact factor: 4.784

9.  Genetic polymorphism in ornithine decarboxylase and risk of breast cancer.

Authors:  Iain Brown; Susan Halliday; Heather Greig; Steven D Heys; Heather M Wallace; Andrew C Schofield
Journal:  Fam Cancer       Date:  2009-02-19       Impact factor: 2.375

10.  Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene.

Authors:  Maria Elena Martinez; Thomas G O'Brien; Kimberly E Fultz; Naveen Babbar; Hagit Yerushalmi; Ning Qu; Yongjun Guo; David Boorman; Janine Einspahr; David S Alberts; Eugene W Gerner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.